LAURENCIN CATO T
Known title: DirectorCIK: 0001444810
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification. A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.
Transaction History
| ALKS | ▼ Sell | Tax Withholding | 1,475 | $55K | 5/21/2026 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 6,142 | — | 5/21/2026 | View on chart |
| MDXG | ▲ Buy | Grant | 28,609 | $185K | 6/18/2025 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 8,013 | — | 5/31/2025 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,924 | $59K | 5/31/2025 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 2,691 | $61K | 12/9/2024 | View on chart |
| ALKS | ▼ Sell | Open Market | 2,691 | $86K | 12/9/2024 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 958 | $30K | 12/8/2024 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 4,163 | — | 12/8/2024 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,465 | $35K | 6/29/2024 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 6,104 | — | 6/29/2024 | View on chart |
| MDXG | ▲ Buy | Grant | 23,190 | $168K | 6/5/2024 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 2,690 | $61K | 2/15/2024 | View on chart |
| ALKS | ▼ Sell | Open Market | 2,690 | $86K | 2/15/2024 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,000 | $26K | 12/8/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 4,163 | — | 12/8/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 5,957 | — | 7/7/2023 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,430 | $43K | 7/7/2023 | View on chart |
| MDXG | ▲ Buy | Grant | 35,354 | $175K | 6/13/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 2,638 | $61K | 6/8/2023 | View on chart |
| ALKS | ▼ Sell | Open Market | 2,638 | $84K | 6/8/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 2,800 | $64K | 6/7/2023 | View on chart |
| ALKS | ▼ Sell | Open Market | 2,800 | $88K | 6/7/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 4,160 | — | 12/8/2022 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 385 | $10K | 12/8/2022 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 4,082 | — | 12/8/2022 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 378 | $10K | 12/8/2022 | View on chart |
| MDXG | ▲ Buy | Grant | 44,191 | $175K | 6/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Baird Highlights Growth Potential for Alkermes plc (ALKS)
Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.
Baird Highlights Growth Potential for Alkermes plc (ALKS). Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.